{"pmid":32275075,"title":"Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China.","text":["Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China.","Coronavirus disease 2019 (COVID-19), an infectious outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),(1) has now progressed to global pandemic.(2) Besides the compelling need to understand the novel biological pathways underlying the virulence and pathogenicity of SARS-CoV-2 in humans to enable the development of appropriate interventions and therapies,(3,4) the noticeable difference in mortality rates between Asian and European populations is one of the most significant issues demanding the attention of biologists, epidemiologists and clinicians around the world. This article is protected by copyright. All rights reserved.","J Med Virol","Lippi, Giuseppe","Mattiuzzi, Camilla","Sanchis-Gomar, Fabian","Henry, Brandon M","32275075"],"abstract":["Coronavirus disease 2019 (COVID-19), an infectious outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),(1) has now progressed to global pandemic.(2) Besides the compelling need to understand the novel biological pathways underlying the virulence and pathogenicity of SARS-CoV-2 in humans to enable the development of appropriate interventions and therapies,(3,4) the noticeable difference in mortality rates between Asian and European populations is one of the most significant issues demanding the attention of biologists, epidemiologists and clinicians around the world. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lippi, Giuseppe","Mattiuzzi, Camilla","Sanchis-Gomar, Fabian","Henry, Brandon M"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275075","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25860","keywords":["COVID-19","comorbidity","coronavirus","epidemics","mortality","outbreak"],"source":"PubMed","locations":["Italy","China"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1663712077827538944,"score":7.9164424,"similar":[{"pmid":32237160,"title":"Epidemiological analysis of COVID-19 and practical experience from China.","text":["Epidemiological analysis of COVID-19 and practical experience from China.","The rapid spread of the epidemic has aroused widespread concern in the international community. SARS-COV-2 originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and MERS, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved. This article is protected by copyright. All rights reserved.","J Med Virol","Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting","32237160"],"abstract":["The rapid spread of the epidemic has aroused widespread concern in the international community. SARS-COV-2 originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and MERS, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237160","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25813","keywords":["COVID-19","epidemic","mortality","treatment","virus pneumonia"],"source":"PubMed","locations":["Chinese","Wuhan","Hubei","China","Huanan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352135527432193,"score":164.7171},{"pmid":32224074,"title":"Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1.","text":["Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1.","BACKGROUND: Since the outbreak of Coronavirus Disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases, such as influenza viruses. RESEARCH QUESTION: The aim of the study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with acute respiratory distress syndrome (ARDS). STUDY DESIGN: and Methods: This was a retrospective case-control study. We compared two independent cohorts of ARDS patients infected with either COVID-19 (n=73) or H1N1 (n=75). We analyzed and compared their clinical manifestations, imaging characteristics, treatments, and prognosis. RESULTS: The median age of COVID-19 patients was higher than that of H1N1 patients, and there was a higher proportion of males among COVID-19 patients (p<0.05). COVID-19 patients exhibited higher proportions of non-productive coughs, fatigue, and gastrointestinal symptoms than those of H1N1 patients (p<0.05). H1N1 patients had higher sequential organ failure assessment (SOFA) scores than COVID-19 patients (p<0.05). The PaO2/FiO2 of 198.2 mmHg in COVID-19 patients was significantly higher than the PaO2/FiO2 of 107.0 mmHg of H1N1 patients (p<0.001). Ground-glass opacities was more common in COVID-19 patients than in H1N1 patients (p<0.001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of COVID-19 patients was 28.8%, while that of H1N1 patients was 34.7% (p=0.483). SOFA-score adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients with the rate ratio was 2.009 (95% CI [1.563, 2.583], p<0.001). INTERPRETATION: There were many differences between COVID-19 and H1N1-induced ARDS patients in clinical presentations. Compared with H1N1, patients with COVID-19 induced ARDS had lower severity of illness scores at presentation and lower SOFA-score adjusted mortality.","Chest","Tang, Xiao","Du, Ronghui","Wang, Rui","Cao, Tanze","Guan, Lulu","Yang, Chengqing","Zhu, Qi","Hu, Ming","Li, Xuyan","Li, Ying","Liang, Lirong","Tong, Zhaohui","Sun, Bing","Peng, Peng","Shi, Huanzhong","32224074"],"abstract":["BACKGROUND: Since the outbreak of Coronavirus Disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases, such as influenza viruses. RESEARCH QUESTION: The aim of the study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with acute respiratory distress syndrome (ARDS). STUDY DESIGN: and Methods: This was a retrospective case-control study. We compared two independent cohorts of ARDS patients infected with either COVID-19 (n=73) or H1N1 (n=75). We analyzed and compared their clinical manifestations, imaging characteristics, treatments, and prognosis. RESULTS: The median age of COVID-19 patients was higher than that of H1N1 patients, and there was a higher proportion of males among COVID-19 patients (p<0.05). COVID-19 patients exhibited higher proportions of non-productive coughs, fatigue, and gastrointestinal symptoms than those of H1N1 patients (p<0.05). H1N1 patients had higher sequential organ failure assessment (SOFA) scores than COVID-19 patients (p<0.05). The PaO2/FiO2 of 198.2 mmHg in COVID-19 patients was significantly higher than the PaO2/FiO2 of 107.0 mmHg of H1N1 patients (p<0.001). Ground-glass opacities was more common in COVID-19 patients than in H1N1 patients (p<0.001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of COVID-19 patients was 28.8%, while that of H1N1 patients was 34.7% (p=0.483). SOFA-score adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients with the rate ratio was 2.009 (95% CI [1.563, 2.583], p<0.001). INTERPRETATION: There were many differences between COVID-19 and H1N1-induced ARDS patients in clinical presentations. Compared with H1N1, patients with COVID-19 induced ARDS had lower severity of illness scores at presentation and lower SOFA-score adjusted mortality."],"journal":"Chest","authors":["Tang, Xiao","Du, Ronghui","Wang, Rui","Cao, Tanze","Guan, Lulu","Yang, Chengqing","Zhu, Qi","Hu, Ming","Li, Xuyan","Li, Ying","Liang, Lirong","Tong, Zhaohui","Sun, Bing","Peng, Peng","Shi, Huanzhong"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224074","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.chest.2020.03.032","keywords":["COVID-19","acute respiratory distress syndrome","influenza A H1N1","mortality"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663352135268433922,"score":145.4049},{"pmid":32092748,"title":"COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.","text":["COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.","Rapidly sharing scientific information is an effective way to reduce public panic about COVID-19, and doing so is the key to providing real-time guidance to epidemiologists working to contain the outbreak, clinicians managing patients, and modelers helping to understand future developments and the possible effectiveness of various interventions. This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies. As an academic journal, we will continue to quickly and transparently share data with frontline healthcare workers who need to know the epidemiological and clinical features of COVID-19.","Biosci Trends","Song, Peipei","Karako, Takashi","32092748"],"abstract":["Rapidly sharing scientific information is an effective way to reduce public panic about COVID-19, and doing so is the key to providing real-time guidance to epidemiologists working to contain the outbreak, clinicians managing patients, and modelers helping to understand future developments and the possible effectiveness of various interventions. This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies. As an academic journal, we will continue to quickly and transparently share data with frontline healthcare workers who need to know the epidemiological and clinical features of COVID-19."],"journal":"Biosci Trends","authors":["Song, Peipei","Karako, Takashi"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32092748","week":"20209|Feb 24 - Mar 01","doi":"10.5582/bst.2020.01056","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","sharing data"],"source":"PubMed","locations":["Chinese","Western"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"e_drugs":["chloroquine diphosphate"],"_version_":1663352134508216320,"score":126.43038},{"pmid":32267098,"title":"Digestive system involvement of novel coronavirus infection: prevention and control infection from a gastroenterology perspective.","text":["Digestive system involvement of novel coronavirus infection: prevention and control infection from a gastroenterology perspective.","An epidemic of an acute respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, now known as coronavirus disease 2019 (COVID-19), beginning in December 2019 has attracted an intense amount of attention worldwide. As the natural history and variety of clinical presentations of this disease unfolds, the extrapulmonary symptoms of the disease have emerged, especially the symptoms related to the digestive system. While the respiratory mode of transmission is well-known and likely the principal mode of transmission of this disease, the possibility of the fecal-oral route of transmission has also emerged in various case series and clinical scenario. In this review article, we summarized the published literatures to date concerning four different aspects: (a) gastrointestinal manifestations of COVID-19 infection; (b) microbiologic and virological investigations; (c) the role of fecal-oral transmission; and (d) prevention/control infection in the digestive endoscopy room. A timely understanding of the relationship between the disease and the digestive system and implementing effective preventive measures are of great significance for a favorable outcome of the disease and can help mitigate further transmission by appropriate measures. This article is protected by copyright. All rights reserved.","J Dig Dis","Li, Lian Yong","Wu, Wei","Chen, Sheng","Gu, Jian Wen","Li, Xin Lou","Song, Hai Jing","Du, Feng","Wang, Gang","Zhong, Chang Qing","Wang, Xiao Ying","Chen, Yan","Shah, Rushikesh","Yang, He Ming","Cai, Qiang","32267098"],"abstract":["An epidemic of an acute respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, now known as coronavirus disease 2019 (COVID-19), beginning in December 2019 has attracted an intense amount of attention worldwide. As the natural history and variety of clinical presentations of this disease unfolds, the extrapulmonary symptoms of the disease have emerged, especially the symptoms related to the digestive system. While the respiratory mode of transmission is well-known and likely the principal mode of transmission of this disease, the possibility of the fecal-oral route of transmission has also emerged in various case series and clinical scenario. In this review article, we summarized the published literatures to date concerning four different aspects: (a) gastrointestinal manifestations of COVID-19 infection; (b) microbiologic and virological investigations; (c) the role of fecal-oral transmission; and (d) prevention/control infection in the digestive endoscopy room. A timely understanding of the relationship between the disease and the digestive system and implementing effective preventive measures are of great significance for a favorable outcome of the disease and can help mitigate further transmission by appropriate measures. This article is protected by copyright. All rights reserved."],"journal":"J Dig Dis","authors":["Li, Lian Yong","Wu, Wei","Chen, Sheng","Gu, Jian Wen","Li, Xin Lou","Song, Hai Jing","Du, Feng","Wang, Gang","Zhong, Chang Qing","Wang, Xiao Ying","Chen, Yan","Shah, Rushikesh","Yang, He Ming","Cai, Qiang"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267098","week":"202015|Apr 06 - Apr 12","doi":"10.1111/1751-2980.12862","keywords":["COVID-19","digestive system","prevention and control","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Prevention","Diagnosis"],"weight":1,"_version_":1663609715729367040,"score":126.06521},{"pmid":32238757,"title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","text":["Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.","J Microbiol Biotechnol","Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun","32238757"],"abstract":["Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19."],"journal":"J Microbiol Biotechnol","authors":["Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238757","week":"202014|Mar 30 - Apr 05","doi":"10.4014/jmb.2003.03011","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","coronavirus","outbreak"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352135440400384,"score":124.17075}]}